Alkahest Announces a Human Trial to Address Cognitive Impairment


Blood filterBlood filter

Alkahest has announced plans to launch a Phase 2 human trial that aims to address cognitive impairment and takes the unusual approach of using an external medical device that filters a harmful protein from the blood of end-stage renal disease patients.

To do this, we need your support. Your charitable contribution tranforms into rejuvenation research, news, shows, and more. Will you help?

The medical device, known as an AKST1210, will be connected in-line with a haemodialysis machine. The AKST1210 is designed to filter out and remove a protein called Beta-2 microglobulin (B2M), which was identified in a 2015 study by Dr. Saul Villeda, who confirmed its role as a pro-aging factor present in old blood [1].

B2M is an immune-associated protein with harmful, pro-inflammatory activity, and its presence has been shown to impair cognitive ability in animal studies. B2M is a problem for patients on long-term hemodialysis, as it can aggregate into amyloid fibers that deposit in joint spaces, a disease known as dialysis-related amyloidosis, and is thought to contribute to cognitive impairment in patients on hemodialysis for end-stage renal disease.

The following is an extract from Alkahest’s official press release:

SAN CARLOS, Calif., June 01, 2020 (GLOBE NEWSWIRE) β€” Alkahest Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases, today announced the initiation of a clinical study to explore the use of an extracorporeal medical device to remove excess Beta-2 microglobulin (B2M) from circulation for the treatment of cognitive impairment in patients undergoing hemodialysis for end stage renal disease (ESRD).

β€œA large proportion of individuals with end-stage renal disease who receive hemodialysis have cognitive impairment, which may be associated with reduced ability for self-care, poor adherence to dietary and fluid restrictions, and poor outcomes,” said Karoly Nikolich, Ph.D., chief executive officer of Alkahest.Β  β€œAlkahest’s preclinical research has demonstrated that Beta-2 microglobulin, which is present at higher levels in older individuals, is drastically elevated in patients undergoing dialysis and may contribute to the high prevalence of cognitive impairment in these individuals. By reducing the amount of B2M in the plasma, we hope to introduce an effective way to lessen this impairment and allow patients on hemodialysis for ESRD to achieve improved treatment outcomes and quality of life.”

AKST1210-201 is a randomized, double-blind, feasibility and tolerability study investigating the use of the AKST1210 device connected to the dialysis circuit in 20 subjects with ESRD and cognitive impairment over a period of 20 weeks. Key objectives are safety and tolerability, as well as feasibility of conducting clinical trials with AKST1210 in this setting. Secondary objectives include measurement of removal of B2M, as well as improvements in clinical measures of cognitive, functional and quality of life assessments.


The B2M protein is one of a number of proteins that have been observed to rise with age, and reducing its presence may help reduce the risk of cognitive impairment for patients on hemodialysis. If the trial is successful, then Alkahest has selected a good therapeutic target with an approach that should be relatively easy to implement.

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. We are committed to responsible journalism, free from commercial or political influence, that allows you to make informed decisions about your future health.

All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent journalism and sustains our future. You can support us by making a donation or in other ways at no cost to you.

NMN Reduces Systolic Blood Pressure in Clinical Trial

Combining human clinical trial research, cellular analysis, and mouse studies, researchers publishing in the Nature journal Signal Transduction and Targeted...

Rejuvenation Roundup September 2023

On some corners of the Internet, "Spooktober", effectively a month-long Halloween, has just begun. Here at Lifespan.io, though, we talk...

Longevity and DeSci Recap – September 2023

Welcome back to the latest edition of the Longevity and DeSci Recap. Here, you’ll discover the latest interviews, insights, and...

Study: Waist-to-Hip Ratio Predicts Mortality Better Than BMI

A new study suggests that waist-to-hip ratio (WHR) has a more linear correlation with all-cause mortality than either body mass...


[1] Smith, L. K., He, Y., Park, J. S., Bieri, G., Snethlage, C. E., Lin, K., … & Wheatley, E. G. (2015). [beta] 2-microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesis. Nature medicine, 21(8), 932-937.

About the author

Steve Hill

Steve serves on the LEAF Board of Directors and is the Editor in Chief, coordinating the daily news articles and social media content of the organization. He is an active journalist in the aging research and biotechnology field and has to date written over 600 articles on the topic, interviewed over 100 of the leading researchers in the field, hosted livestream events focused on aging, as well as attending various medical industry conferences. His work has been featured in H+ magazine, Psychology Today, Singularity Weblog, Standpoint Magazine, Swiss Monthly, Keep me Prime, and New Economy Magazine. Steve is one of three recipients of the 2020 H+ Innovator Award and shares this honour with Mirko Ranieri – Google AR and Dinorah Delfin – Immortalists Magazine. The H+ Innovator Award looks into our community and acknowledges ideas and projects that encourage social change, achieve scientific accomplishments, technological advances, philosophical and intellectual visions, author unique narratives, build fascinating artistic ventures, and develop products that bridge gaps and help us to achieve transhumanist goals. Steve has a background in project management and administration which has helped him to build a united team for effective fundraising and content creation, while his additional knowledge of biology and statistical data analysis allows him to carefully assess and coordinate the scientific groups involved in the project.
No Comments
Write a comment:


Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.